MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
IPO Year: 2014
Exchange: NASDAQ
Website: mymd.com
DEF 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
S-3 - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K/A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
PRE 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
D - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
D - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)